Lead Product(s) : Palazestrant,Atirmociclib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Olema Oncology Announces New Clinical Trial Agreement with Pfizer
Details : The companies will evaluate in a Phase 1b/2 study the safety and combinability of OP-1250 (palazestrant) plus PF-07220060 (atirmociclib), in metastatic breast cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 02, 2025
Lead Product(s) : Palazestrant,Atirmociclib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Palazestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Palazestrant with Ribociclib as First-line Treatment in ER+/HER2- Advanced Breast Cancer
Details : Palazestrant is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2025
Lead Product(s) : Palazestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palazestrant,Ribociclib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Adage Capital Partners
Deal Size : $250.0 million
Deal Type : Private Placement
Olema & Novartis Collaborate on Breast Cancer Trials, Raise $250M Equity Placement
Details : The net proceeds will be used to fund the clinical development of company's lead product OP-1250 (palazestrant), which is being evaluated for the treatment of ER+/HER2-metastatic breast cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 02, 2024
Lead Product(s) : Palazestrant,Ribociclib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Adage Capital Partners
Deal Size : $250.0 million
Deal Type : Private Placement
Lead Product(s) : Palazestrant,Ribociclib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Olema & Novartis Collaborate on Breast Cancer Trials, Raise $250M Equity Placement
Details : Through collaboration, Novartis will provide Olema with ribociclib for the planned late-stage OP-1250 (palazestrant) trial with ribociclib in ER+/HER2-metastatic breast cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 02, 2024
Lead Product(s) : Palazestrant,Ribociclib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Palazestrant,Ribociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
Details : Under the collaboration, Novartis will increase the size of the ongoing Phase 1/2 study testing OP-1250 (palazestrant), an orally-available small molecule with dual activity as both a complete ER antagonist and a selective ER degrader, in combination wit...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : Palazestrant,Ribociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Palazestrant,Palbociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Paradigm BioCapital
Deal Size : $130.0 million
Deal Type : Private Placement
Olema Oncology Announces Combined Financing for up to $180 Million
Details : Olema intends to use the net proceeds to fund research and development of palazestrant OP-1250 (palazestrant), a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist and a selective ER degra...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 05, 2023
Lead Product(s) : Palazestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Paradigm BioCapital
Deal Size : $130.0 million
Deal Type : Private Placement
Lead Product(s) : Palazestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Details : Palazestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 30, 2023
Lead Product(s) : Palazestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palazestrant,Palbociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OP-1250 is an estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), which is being investigated in combination with palbociclib, a CDK4/6 inhibitor, for the treatment of ER+/HER2- metastatic breast cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 11, 2023
Lead Product(s) : Palazestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palazestrant,Palbociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OP-1250 demonstrated favorable pharmacokinetics characterized by high oral bioavailability, dose proportional exposure and a long half-life of eight days, with steady-state plasma levels showing minimal peak-to-trough variability, enabling consistent inh...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2022
Lead Product(s) : Palazestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palazestrant
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2022
Lead Product(s) : Palazestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable